Daan Gene saw the highest growth of 2.99% in patent filings in May and 0.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Daan Gene’s patent filings and grants. Buy the databook here.
Daan Gene has been focused on protecting inventions in China(CN) with four publications in Q2 2024
The China(CN) Patent Office dominates the patent filings and grants with nearly 33% filings and 100% grants. The World Intellectual Property Organization(WIPO), China(CN), and European Patent Office(EPO) patent Office are among the top ten patent offices where Daan Gene is filings its patents. Among the top granted patent authorities, Daan Gene has 100% of its grants in China(CN).
Chinese Academy of Sciences and Roche could be the strongest competitors for Daan Gene
Patents related to healthtech and rare diseases lead Daan Gene's portfolio
Daan Gene has the highest number of patents in healthtech followed by, rare diseases and digitalization. For healthtech, nearly 33% of patents were filed and no patents were granted in Q2 2024.
Laboratory equipment related patents lead Daan Gene portfolio followed by tuberculosis, and consumer devices
Daan Gene has highest number of patents in laboratory equipment followed by tuberculosis, consumer devices, consumer applications, and music, images, & video.
For comprehensive analysis of Daan Gene's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.